Agoracom Blog

CLIENT FEATURE: Valeo Pharma $ $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $ $ $ $

Posted by AGORACOM-JC at 12:04 PM on Wednesday, January 13th, 2021


Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Click below to read in its entirety.

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , , , , , ,

Comments are closed.